Tetraphase Pharmaceuticals, Inc. (TTPH) Short Interest Update
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 3,889,264 shares, a growth of 32.8% from the August 15th total of 2,927,894 shares. Approximately 7.7% of the company’s stock are short sold. Based on an average daily trading volume, of 856,396 shares, the days-to-cover ratio is presently 4.5 days.
In other news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total transaction of $105,000.00. Following the completion of the sale, the insider now directly owns 17,500 shares of the company’s stock, valued at approximately $105,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 5.50% of the company’s stock.
A number of institutional investors have recently bought and sold shares of TTPH. AXA purchased a new stake in Tetraphase Pharmaceuticals during the second quarter valued at $132,000. Teza Capital Management LLC increased its position in Tetraphase Pharmaceuticals by 8.9% during the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 1,281 shares during the last quarter. Citadel Advisors LLC increased its position in Tetraphase Pharmaceuticals by 18.6% during the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 2,496 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in Tetraphase Pharmaceuticals during the second quarter valued at $147,000. Finally, Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares during the last quarter. Institutional investors own 41.73% of the company’s stock.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 6.94 on Friday. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93. The stock’s market cap is $354.31 million. The company has a 50-day moving average price of $6.28 and a 200 day moving average price of $7.27.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). The firm had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The firm’s revenue was up 28.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.47) EPS. Equities research analysts expect that Tetraphase Pharmaceuticals will post ($2.54) earnings per share for the current year.
TTPH has been the subject of several research analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Tuesday. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research report on Wednesday, August 9th. HC Wainwright initiated coverage on Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They set a “buy” rating and a $15.00 target price for the company. BidaskClub raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $10.88.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.